This study review presents the two-year safety and efficacy outcomes of bimekizumab from two phase 3 trials.
Independent commentary for the review has been provided by Dr Ai Tran, a Consultant Rheumatologist at St John of God, Murdoch in Western Australia.
Please login below to download this issue (PDF)